Astria Therapeutics

ATXS

Market cap $673M

ATXS stock jumps 37% after agreeing to a $700 million cash-and-stock buyout by BioCryst, boosting the latter's HAE treatment pipeline.

NEW YORK, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

NEW YORK , Oct. 14, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Astria Therapeutics, Inc. (NASDAQ:  ATXS ) related to its sale to BioCryst Pharmaceuticals, Inc. Under the terms of the proposed transaction, Astria shareholders will receive $8.55 in cash per share and 0.59 shares of BioCryst common stock per Astria share.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) on Tuesday agreed to acquire Astria Therapeutics, Inc. (NASDAQ:ATXS) for a mix of cash and stock.

MILWAUKEE , Oct. 14, 2025 /PRNewswire/ -- The Ademi Firm is investigating Astria (NASDAQ: ATXS) for possible breaches of fiduciary duty and other violations of law in its transaction with BioCryst. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Astria Therapeutics, Inc. (NASDAQ: ATXS) to BioCryst Pharmaceuticals, Inc. for $8.55 in cash per share and 0.59 shares of BioCryst common stock per share of Astria is fair to Astria shareholders. Halper Sadeh encourages Astria shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.co.

BioCryst Pharmaceuticals said on Tuesday it would buy Astria Therapeutics in a cash-and-stock deal valued at about $700 million, as it looks to expand its portfolio of treatments for rare diseases.

RESEARCH TRIANGLE PARK, N.C., & BOSTON--(BUSINESS WIRE)--BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) and Astria Therapeutics, Inc. (Nasdaq: ATXS) today announced that the companies have entered into a definitive agreement under which BioCryst has agreed to acquire Astria, a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, for a mix of cash and stock representing an implied value of $13.00 per Astria share, and approximately $700 mi.

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present two posters at the Canadian Society of Allergy and Clinical Immunology (CSACI) 80th Anniversary Scientific Meeting, taking place October 15-18, 2025 in Vancouver, British Columbia. Dr. Adil Adatia, M.D., FRCPC, University of Alberta, Edmonton, AB will share initial results from the.

BOSTON, Mass.--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced the initiation of the Phase 3 ORBIT-EXPANSE long-term trial of navenibart in people living with hereditary angioedema (HAE). “The initiation of ORBIT-EXPANSE marks exciting progress in the development of navenibart,” said Christopher Morabito, M.D., Chief Medical Officer at Astria Therapeutics. ".